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Background. Although outpatient parenteral antimicrobial therapy (OPAT) is generally considered safe, patients are at risk for 
complications and thus require close monitoring. The purpose of this study is to determine how OPAT programs are structured and 
how United States–based infectious diseases (ID) physicians perceive barriers to safe OPAT care.
Methods. We queried members of the Emerging Infections Network (EIN) between November and December 2018 about prac-
tice patterns and barriers to providing OPAT.
Results. A total of 672 members of the EIN (50%) responded to the survey. Seventy-five percent of respondents were actively 
involved in OPAT, although only 37% of respondents reported that ID consultation was mandatory for OPAT. The most common 
location for OPAT care was at home with home health support, followed by post–acute care facilities. Outpatient and inpatient ID 
physicians were identified as being responsible for monitoring laboratory results (73% and 54% of respondents, respectively), but 
only 36% had a formal OPAT program. The majority of respondents reported a lack of support in data analysis (80%), information 
technology (66%), financial assistance (65%), and administrative assistance (60%). The perceived amount of support did not differ 
significantly across employment models. Inability to access laboratory results in a timely manner, lack of leadership awareness of 
OPAT value, and failure to communicate with other providers administering OPAT were reported as the most challenging aspects 
of OPAT care.
Conclusions. ID providers were highly involved in OPAT, but only one-third of respondents had a dedicated OPAT program. 
Lack of financial and institutional support were perceived as significant barriers to providing safe OPAT care.
Keywords. antimicrobial use; care delivery; OPAT; practice management; patient safety.
Outpatient parenteral antimicrobial therapy (OPAT) is a con-
venient approach for delivering parenteral antibiotics outside 
the hospital setting [1, 2]. OPAT shortens hospital stays, de-
creases health care expenditures, and increases patient satis-
faction [3–5]. OPAT is effective and generally considered safe 
[6] but requires close monitoring for therapy-related compli-
cations and treatment failure [7, 8]. The standard of care for 
monitoring patients receiving OPAT includes clinical follow-up 
and at least weekly monitoring of clinical laboratory results [9]. 
OPAT monitoring programs designed to ensure safe and effec-
tive care are labor-intensive [10]. A  2013 survey of infectious 
diseases (ID) physicians queried through Centers for Disease 
Control and Prevention (CDC)–sponsored Emerging Infections 
Network (EIN) reported that only one-quarter of respondents 
had a dedicated OPAT program. Those ID physicians reported 
that the lack of a dedicated OPAT team, the large number of lo-
cations in which patients received OPAT, insufficient commu-
nication between health care workers, and a large volume of 
laboratory results were the most common barriers to the safe de-
livery of OPAT [10]. In another national survey of ID physicians 
administering OPAT, systemic laboratory test result tracking, 
communication between inpatient and outpatient providers, 
and adherence to clinic visits were more likely to occur in prac-
tices with a formal OPAT program [11]. In an era where OPAT 
may be rapidly expanding due to increasing pressure to decrease 
length of stay and decrease costs, we surveyed ID physicians in 
the EIN to better clarify how OPAT patients are managed and to 
identify barriers to the safe care of OPAT patients.
METHODS
Instrument
We developed a survey instrument in collaboration with ID 
physicians and EIN staff, with technical assistance from the 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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CDC. The instrument contained 10 multiple choice or Likert-
style items and 1 free-text item allowing respondents to provide 
additional comments. The survey was piloted with a group of 
content experts, and questions were modified based on their 
feedback. The survey focused on the respondents’ role with 
OPAT, location where OPAT is received, providers responsible 
for managing OPAT, time devoted to OPAT, institutional sup-
port given to OPAT, and barriers to safe OPAT care (Appendix 
Table 1).
Study Population and Distribution
The EIN is a CDC-supported volunteer-based group of prac-
ticing ID physician members of the Infectious Diseases Society 
of America (IDSA). Approximately 20% of ID physicians in 
clinical practice in the United States are members of the EIN 
[12]. The EIN was established as a provider-based emerging 
infections surveillance network that communicates regularly 
about emerging infectious diseases and related phenomena. 
EIN members also volunteer to complete surveys. Baseline geo-
graphic and practice characteristics for EIN members are main-
tained in a database and updated regularly.
EIN members were sent the confidential survey by email 
link or by facsimile and could complete the survey between 
November 14, 2018, and December 17, 2018. Nonresponders 
were given 2 reminders after the initial request to complete the 
survey. Similar to previous EIN surveys, the response rate was 
calculated from EIN members who had ever responded to a 
survey [12].
Participants who reported having a role with OPAT were eli-
gible to answer the survey. Participants were asked to comment 
on OPAT as it occurs at the primary hospital where they work.
Data Analysis
Categorical data were presented using frequencies. For cat-
egorical variables, the chi-square test or analysis of variance 
(ANOVA) was performed as applicable. We were interested 
in what resources might be available to ID physicians with 
different employment structures (ie, working in a military or 
Veterans Administration facility, employed by a hospital or 
clinic, working in a private or group practice, or working in an 
academic medical center). Differences were considered statisti-
cally significant if P < .05.
To assess for the possibility of nonresponse bias, we com-
pared geographic and practice characteristics between respond-
ents and nonrespondents.
All quantitative analyses were performed using SAS 9.4 soft-
ware (Cary, NC).
We also analyzed qualitative data. Participants were asked to 
respond to the item “additional comments about OPAT and re-
lated safety issues” with free-text responses. Two authors (Y.H., 
S.K.) systematically read the responses and derived codes. 
They reached agreement on classification of the responses. 
Percentages of respondents answering the item and illustrative 
quotes are presented.
RESULTS
Of 1353 active EIN physician members with an adult ID prac-
tice, 672 (50%) responded to the survey. Respondents were 
more likely than nonrespondents to have >25 years of experi-
ence (30% vs 22%; P < .01). Respondents were more likely than 
nonrespondents to be employed at a Veterans Affairs facility 
and less likely to be employed at a medical school (6.1% vs 4.4% 
and 32.6% vs 35.1%, respectively; P = .03). No significant dif-
ferences were identified in regional distribution, primary hos-
pital type, hospital size, or percentage of respondents who were 
fellows-in-training (Supplementary Table 1). One hundred 
sixty-five members (25%) did not have any role in managing 
OPAT patients and were excluded, leaving 507 respondents to 
answer the survey questions.
Two hundred eighteen (43%) respondents had recom-
mended OPAT as an inpatient consultant, whereas 410 (81%) 
had seen OPAT patients in clinic after hospital discharge (Table 
1). Only 37% of respondents (n = 186) reported that ID con-
sultation was mandated in their hospital before discharging pa-
tients on OPAT. However, the majority of respondents (n = 344, 
68%) reported that >75% of patients discharged on intravenous 
antibiotics were managed by ID as outpatients. Outpatient and 
inpatient ID physicians were most frequently identified as being 
responsible for monitoring laboratory results (73% and 54% of 
respondents, respectively). A minority of respondents (n = 182, 
36%) used a dedicated OPAT program or service to monitor 
patients. The majority of respondents felt that the rate of com-
plications did not change (n = 191, 37%) or decreased (n = 165, 
33%) over the past 5 years.
Receipt of OPAT at home with assistance of home health 
or home infusion agencies was the most common OPAT de-
livery method, followed by receipt of OPAT at post–acute care 
facilities (skilled nursing facilities, subacute or acute rehabili-
tation facilities, and long-term acute care facilities) (Figure 1). 
Interestingly, 32% of respondents rated an infusion center as the 
most or second most common OPAT delivery method in their 
practice (n = 147), and 30% of respondents rated home without 
assistance from home infusion or home health as the most or 
second most common OPAT delivery method in their practice 
(n = 127). Most respondents (n = 314, 62%) indicated that ID 
physicians spent at least 4 hours per week on OPAT (Figure 2). 
Many respondents also noted that nurses spent at least 4 hours 
per week on OPAT (n = 220, 51%).
Respondents described the adequacy of support for OPAT. 
Most respondents (n  =  283, 64.6%) felt that OPAT services 
are not well supported financially. Most participants felt that 
administrative support levels (n  =  263, 59.8%), information 
technology support levels (n = 284, 66.2%), and data support 
levels (n = 330, 80.2%) were not adequate for the care of OPAT 
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patients. These perceptions did not vary across employment 
structures (data not shown).
Barriers to safe OPAT care reported as challenging or very 
challenging by over half of respondents included laboratory 
results not returning in a timely fashion (n  =  292, 58.5%), 
leadership not valuing OPAT (n = 293, 58.4%), and struggles 
communicating with OPAT providers (eg, post–acute care fa-
cilities and infusion centers; n = 273, 54.4%) (Table 2). In addi-
tion, many respondents noted that barriers including failure to 
follow up with infectious diseases (n = 241, 47.9%), volume of 
laboratory results to review (n = 241, 47.8%), lack of clinicians 
reviewing laboratory test results (n = 228, 45.2%), and difficulty 
using the electronic medical record system (n  =  219, 43.5%) 
were challenging or very challenging. There were no statisti-
cally significant differences among perceptions of barriers when 
respondents were compared among different employment set-
tings (data not shown).
Free-text comments were received from 85 participants 
(Table 3). Common themes included poor communication be-
tween outpatient ID providers and those delivering OPAT (eg, 
post–acute care facilities, hemodialysis centers, etc.) and poor 
communication between inpatient and outpatient OPAT pro-
viders at the time of hospital discharge (n = 32, 37.6%), lack of 
financial support (n = 20, 23.5%), inadequate care coordination 
especially regarding obtaining laboratory test results (n  =  18, 
21.2%), and poor patient selection (n = 18, 21.2%). As one re-
spondent explained, “The value of a formal OPAT service is to 
an insurer mix, not to the hospital, so it has been a non-starter 
to ask for the hospital to pay to support a team of OPAT phar-
macists that in essence reduces costs to a [third] party.” Some 
discussed the high-risk nature of OPAT and the need for ID in-
volvement in management; one respondent stated, “The further 
the process gets from my office, the more dangerous it feels.” 
However, many still believed OPAT was a necessary part of ID 
clinical care; one respondent stated, “All ID doc[tors] should 
have OPAT in the out[patient] practice.”
DISCUSSION
We found that ID physician involvement in OPAT was high, but 
that ID physicians caring for OPAT patients perceived multiple 
barriers to safe care. Although ID physicians provided care for 
the majority of OPAT patients and had primary responsibility 
for laboratory monitoring, only one-third of respondents used 
a dedicated OPAT program. Receipt of OPAT at home with as-
sistance from home health nursing remains the most common 
model for OPAT delivery [10]. The most common barriers to 
delivering high-quality and safe care for OPAT patients were 
lack of leadership support for OPAT, lack of timely receipt of 
laboratory results, and difficulties in communication with 
post–acute care providers.
As it was first used among children with cystic fibrosis for 
management of pulmonary infections 4 decades ago [13], OPAT 
has been used in multiple settings to treat long-term infections 
and save the hospitals, payers, and the health care system money 
[14, 15]. However, the ID physicians who manage these patients 
perceive that the effort and time spent in OPAT oversight are 
not well-reimbursed [16]. This heavy burden of uncompensated 
care shouldered by ID physicians may contribute to the spe-
cialty being among the lowest-compensated medical specialties 
[17]. In our study, managing these patients, tracking and re-
viewing laboratory test results, managing adverse drug events, 
monitoring and preventing venous catheter complications, 
and monitoring the underlying infection took ID physicians 
Table 1. Employment and OPAT Structures as Reported by 507 Infectious 
Diseases Physicians in the Emerging Infections Network Who Were 
Involved in OPAT
Characteristics No. (%)
Employment
 Hospital or clinic 185 (36.45)
 Private or group practice 146 (28.8)
 University or medical school 145 (28.6)
 Veterans Affairs, military, or federal facility 31 (6.1)
Role in OPATa
 Recommend OPAT as an inpatient consultant 218 (43.0)
 Responsible for placing OPAT orders as an  
inpatient consultant
338 (66.7)
 See patients receiving OPAT in clinic after  
hospital discharge
410 (80.9)
 Manage OPAT program or clinic, or primary person responsible 
for managing OPAT
167 (32.9)
 Initiate OPAT in outpatients 6 (1.2)
 Remotely monitor OPAT 8 (1.6)
Percentage of OPAT patients managed by infectious diseases (answered by 
449)
 <26 41 (8.1)
 26–50 15 (3.0)
 51–75 49 (9.7)
 76–100 344 (67.9)
Labs followed bya:
 Discharging physician 32 (6.3)
 Primary care provider 53 (10.5)
 Skilled nursing facility provider 118 (23.3)
 Home infusion pharmacist 146 (28.8)
 Inpatient infectious diseases physician 267 (52.7)
 OPAT service 182 (35.9)
 Outpatient infectious diseases physician 369 (72.8)
 Infectious diseases nurse 4 (0.8)
 Another team (such as surgery, hospitalist, etc.) 2 (0.4)
 No one 4 (0.8)
Change in frequency of OPAT-related complications over the last 5 y (an-
swered by 447)
 Much more frequent 18 (4.0)
 Somewhat more frequent 73 (16.3)
 No change 191 (42.7)
 Somewhat less frequent 131 (29.3)
 Much less frequent 34 (7.6)
Abbreviations: OPAT, outpatient parenteral antimicrobial therapy.
aRespondents were able to select all responses that applied; numbers add to more than 
100%.
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a significant amount of time on a weekly basis: 62% stated 
that they spent at least 4 hours a week on OPAT. Beyond fol-
low-up clinic visits, obtaining compensation for this time from 
insurers is difficult in the absence of a hospital-based OPAT 
program. Possibly as a result, most ID physicians in our survey 
felt that inadequate financial support for OPAT was a challenge. 
Respondents also noted poor administrative, data analysis, and 
information technology support. Significantly, more than half 
ID physician (n=503)
Considerable (>20 h)
53 261 159 8
114
50
36
015 78 190
44 43 201
93 117 82
106 76 65
Moderate (>4–20 h) Minimal (≤4 h)
RN/LPN (n=433)
No/none
Pharmacist (n=426)
NP/PA (n=397)
Other physician (n=388)
0 50 100 150 200 250
Number who selected each option
300 350 400 450 500
Figure 2. Respondents rated the amount of time spent in a usual week managing outpatient parenteral antimicrobial therapy patients by each of the health care workers 
listed. The numbers are the total number of participants who responded in each category. Abbreviations: ID, infectious diseases; LPN, license practical nurse; NP, nurse prac-
titioner; RN, registered nurse; PA, physician’s assistant.
Dialysis center (n=470)
0 50 100 150 200 250
Number who selected each rank order
300 350 400 450 500
Home with assistance from home
infusion/home health (n=495)
Most common Somewhat common
362
42
38
58
25 144 2974
69 51 248
109 109 202
237 149 63
63 28 42
Less common Least common
Skilled nursing facility or
long-term care facility (n=491)
Infusion center (oce-, clinic-, or
hospital-based; n = 491)
Home without assistance from home
infusion/home health but with
follow-up in clinic (n=426)
Figure 1. Respondents ranked outpatient parenteral antimicrobial therapy delivery sites from the most to least common.
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of respondents stated that a barrier to safe OPAT provision was 
a lack of hospital leadership awareness of the value of OPAT. 
This lack of leadership awareness may contribute to a perceived 
lack of support. These barriers were similar no matter the type 
of hospital the ID physician worked in or the type of employ-
ment structure.
Meanwhile, the lack of hospital leadership awareness of the 
value of OPAT may explain why only 36% of respondents had 
dedicated OPAT programs. This is an increase over the 26% of 
EIN survey respondents who reported having a dedicated OPAT 
team in 2013 but is still only a minority of respondents [10]. The 
presence of a formal OPAT program has been associated with 
implementation of safer OPAT practices such as systematic lab-
oratory test result tracking and ensuring patient adherence to 
clinic visits [11]. A structured OPAT program and formal OPAT 
care team have recently been reported as among the most im-
portant quality indicators in OPAT care [18]. Recognition of 
the value of OPAT by hospital leadership may aid further dis-
semination of dedicated OPAT programs and result in improve-
ments in the quality of OPAT care.
More than one-third (37%) of respondents reported manda-
tory ID consultation before OPAT. Although this is somewhat 
higher than the 22% of respondents who reported mandatory 
ID consultation before OPAT in a 2013 survey [10], this is still 
a minority of respondents. Researchers have shown that man-
datory ID consultation before OPAT prescription promotes 
antimicrobial stewardship by identifying patients who can be 
narrowed or switched to oral agents [19]. In fact, ID-led OPAT 
improves outcomes compared with OPAT not led by ID phys-
icians, with decreased rates of emergency department visits and 
hospitalizations and decreased health care expenditures [20]. 
Where possible, more hospitals may consider requiring ID con-
sultation before OPAT prescription. In addition, it is possible 
that some hospitals lack ID capacity to staff all OPAT patients 
before discharge. In the absence of adequate ID capacity for 
mandatory in-person consultation, formal remote ID evalu-
ation via telemedicine, brief case review, or other innovations 
could improve antimicrobial stewardship and quality of care. 
However, despite the low proportion of respondents who de-
scribed mandatory ID consultation for OPAT patients, our ID 
respondents still reported caring for the vast majority of pa-
tients on OPAT.
In this survey, a newer form of OPAT delivery, self-OPAT 
(where the patient or family member would perform all OPAT care 
at home in the absence of home health assistance but with close 
follow-up in clinic) was used by some respondents [9]. Self-OPAT, 
a novel form of OPAT delivery, has been associated with similar or 
better outcomes (readmission or mortality within 30 days of hos-
pital discharge) when compared with other OPAT models [21].
Respondents identified challenges related to communicating 
with other OPAT providers to be a significant barrier to safe care. 
Specifically, respondents in our survey described difficulty com-
municating with health care workers at the post–acute care fa-
cilities and unclear ownership of patients. Receiving OPAT at 
post–acute care facilities has been associated with higher readmis-
sion rates and higher risk of venous catheter complications [22, 23]. 
Implementation of robust OPAT services could serve as an impor-
tant point of continuity as patients transition across sites of care.
The strengths of this study include the large number of re-
spondents and high response rate (close to 50%). Respondents 
included 1 in 10 ID physicians in the United States and were 
representative of ID physicians in the United States, including 
different regions of the country and different health systems 
and employment models. However, our study has limitations. 
Although EIN is representative of US-based ID physicians, it is 
possible that ID physicians outside the network have different 
practice patterns. Respondents were more likely to be more ex-
perienced physicians, though the difference, while statistically 
significant, was relatively small. We did not capture experiences 
of OPAT from non–ID physician perspectives (eg, OPAT that 
Table 2. Perceptions of Barriers to Safe OPAT Care Among 507 Infectious Diseases Physicians in the Emerging Infections Network Who Had a Role 
Caring for Patients on Outpatient Parenteral Antimicrobial Therapy; Proportion of Respondents Who Rated the Barriers as Challenging or Very Challenging 
Recorded
Barrier Perceived as Challenging or Very Challenging, No. (%)
Laboratory results do not return in a timely fashion (missing = 8) 292 (58.5)
Leadership does not value OPAT (missing = 5) 293 (58.4)
Failure to communicate with other OPAT providers (eg, post–acute care facility, infusion center, etc.; 
missing = 5)
273 (54.4)
Failure to follow up with infectious diseases (missing = 4) 241 (47.9)
Too many laboratory results on OPAT patients to review (missing = 3) 241 (47.8)
No one is reviewing laboratory results on OPAT patients (missing = 3) 228 (45.2)
Difficulty using the electronic medical record system (missing = 4) 219 (43.5)
Cannot get prescribed agents for OPAT after discharge (missing = 5) 129 (25.7)
Unclear who has ownership over patient cases (missing = 3) 121 (24.0)
Patients referred for OPAT who are inappropriate for OPAT (missing = 4) 100 (19.9)
Cannot identify patients appropriate for OPAT (missing = 8) 78 (15.6)
Abbreviation: OPAT, outpatient parenteral antimicrobial therapy.
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may be prescribed by oncologists or the perspectives of ad-
vanced practitioners). In addition, we asked respondents about 
their experiences with OPAT, which may have been subject to 
recall bias. However, we feel that our study did capture ID phys-
icians’ experiences with providing OPAT.
Our study highlighted the high rate of involvement of ID pro-
viders in managing OPAT patients both before and after hospital 
discharge. Lack of support was common across practice settings. 
Efforts are needed to improve awareness of OPAT value among 
health care systems leaders and policy makers in order to estab-
lish OPAT programs that can help improve patient safety.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted ma-
terials are not copyedited and are the sole responsibility of the authors, so ques-
tions or comments should be addressed to the corresponding author.
Acknowledgments
Financial support. This publication was supported by the Cooperative 
Agreement Number, 1 U50 CK000477, funded by the Centers for Disease 
Control and Prevention. Its contents are solely the responsibility of the au-
thors and do not necessarily represent the official views of the Centers for 
Disease Control and Prevention or the Department of Health and Human 
Services. This work was also supported by the Agency for Healthcare 
Research and Quality (1K08HS025782-01 to S.C.K.).
Potential conflicts of interest. All authors: no reported conflicts of in-
terest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. Petrak RM, Skorodin NC, Fliegelman RM, et al. Value and clinical impact of an 
infectious disease-supervised outpatient parenteral antibiotic therapy program. 
Open Forum Infect Dis 2016; 3(X):XXX–XX.
2. Cox AM, Malani PN, Wiseman SW, Kauffman CA. Home intravenous antimicro-
bial infusion therapy: a viable option in older adults. J Am Geriatr Soc 2007; 
55:645–50.
Table 3. Free-Response Concerns Raised About Safe Provision of OPAT; Number and Percentage of 85 Who Responded to Items Shown
Concern Raised
Frequency of Respondents 
Raising Concern, No. (%) Illustrative Quote
Poor communication 32 (37.6) “[Our] biggest problems are in patients who go to [skilled nursing facilities]—they don’t do 
the labs, don’t send patient for [follow-up] appointment[s], etc.”
“Communication about [intravenous] antibiotics being continued after discharge at out-
side hemodialysis centers, nursing homes, and skilled nursing facilities is almost non-
existent. I can only assume that the orders are being carried out, appropriate labs are 
being monitored.”
“At times, I feel there is no involvement from other care providers in hospital [which leads 
to] dumping patients out in the community on [intravenous] antibiotics, and it’s often 
impossible to get them to re-evaluate these same patients.”
Financial reimbursement 20 (23.5) “[I wonder] why physicians sometimes benefit financially from OPAT. [I am] curious how 
prevalent this is.”
“Poor Medicare coverage for elderly patients also complicates [my] ability to choose safe 
medications for home infusion.”
“The value of a formal OPAT service is to an insurer mix, not to the hospital, so it has 
been a non-starter to ask for the hospital to pay to support a team of OPAT pharmacists 
that in essence reduces costs to a [third] party.”
Inadequate care coordination 18 (21.2) “[There is a] significant delay in getting labs from home health. Our facility employs a [reg-
istered nurse] to oversee labs and track them down, but prior to this it was extremely 
challenging. [We] often did not get labs at all and many [of our] patients [were] lost to 
follow-up.”
“We have a very strong OPAT program send about 100–150 people home each month 
on [intravenous] treatment. [We have a] rare safety issue where a patient may go to a 
facility that is far out of our ‘jurisdiction’ and it is not easy to get information or labs, but 
that is rare.”
“I pay a [nurse practitioner/physician’s assistant] to help follow OPAT pts and help me 
make sure that balls are not dropped.”
Poor patient selection 18 (21.2) “In the urban…area where I practice over 50% of the patients who get OPAT could be 
better managed with oral antimicrobials.”
“I follow[ed] all my [intravenous antibiotic patients] in the past, [but] less so now with 
[intravenous] heroin [users who develop] endocarditis as it’s a big time investment with 
lots of noncompliance and little ethical or financial reward.”
Poor follow-up 14 (16.5) “[For example, an] ID progress note suggested weekly CPK monitoring for patient on 
daptomycin. The suggestion was mistakenly transcribed as CRP. [The] patient returned 
to [the] hospital three weeks later with severe myalgias, cough, and [a] CPK of 20 000.”
“The hardest is when a person is being discharged from another facility and their provider 
wants to follow the patient—yet my name goes on the orders.”
Medicolegal liability 4 (4.7) “[The] cost and liability are being shifted from the hospital (and administration) to the ID 
practitioner, without concurrent clerical and technical support.”
“The further the process gets from my office, the more dangerous it feels.”
Abbreviations: CPK, creatinine phosphokinase; CRP, C-reactive protein; ID, infectious diseases; OPAT, outpatient parenteral antimicrobial therapy.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/6/10/ofz363/5552085 by W
ashington U
niversity, Law
 School Library user on 23 N
ovem
ber 2019
ID Physicians’ Perspectives on OPAT • ofid • 7
3. Nguyen HH. Hospitalist to home: outpatient parenteral antimicrobial therapy at 
an academic center. Clin Infect Dis 2010; 51(Suppl 2):S220–3.
4. Yan M, Elligsen M, Simor AE, Daneman N. Patient characteristics and outcomes 
of outpatient parenteral antimicrobial therapy: a retrospective study. Can J Infect 
Dis Med Microbiol 2016; 2016:8435257.
5. Wai AO, Frighetto L, Marra CA, et al. Cost analysis of an adult outpatient paren-
teral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and 
Ministry of Health perspective. Pharmacoeconomics 2000; 18:451–7.
6. Ruh CA, Parameswaran GI, Wojciechowski AL, Mergenhagen KA. Outcomes and 
pharmacoeconomic analysis of a home intravenous antibiotic infusion program 
in veterans. Clin Ther 2015; 37:2527–35.
7. Hale  CM, Steele  JM, Seabury  RW, Miller  CD. Characterization of drug-related 
problems occurring in patients receiving outpatient antimicrobial therapy. J 
Pharm Pract 2017; 30:600–5.
8. Lee B, Tam I, Weigel B 4th, et al. Comparative outcomes of β-lactam antibiotics 
in outpatient parenteral antibiotic therapy: treatment success, readmissions and 
antibiotic switches. J Antimicrob Chemother 2015; 70:2389–96.
9. Norris AH, Shrestha NK, Allison GM, et al. 2018 Infectious Diseases Society of 
America clinical practice guideline for the management of outpatient parenteral 
antimicrobial therapy. Clin Infect Dis 2019; 68:e1–35.
10. Lane MA, Marschall J, Beekmann SE, et al. Outpatient parenteral antimicrobial 
therapy practices among adult infectious disease physicians. Infect Control Hosp 
Epidemiol 2014; 35:839–44.
11. Muldoon EG, Switkowski K, Tice A, et al. A national survey of infectious disease 
practitioners on their use of outpatient parenteral antimicrobial therapy (OPAT). 
Infect Dis 2015; 47:39–45.
12. Pillai  SK, Beekmann  SE, Santibanez  S, Polgreen  PM. The Infectious Diseases 
Society of America Emerging Infections Network: bridging the gap between clin-
ical infectious diseases and public health. Clin Infect Dis 2014; 58:991–6.
13. Rucker RW, Harrison GM. Outpatient intravenous medications in the manage-
ment of cystic fibrosis. Pediatrics 1974; 54:358–60.
14. Paladino  JA, Poretz  D. Outpatient parenteral antimicrobial therapy today. Clin 
Infect Dis 2010; 51(Suppl 2):S198–208.
15. Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral 
cephalosporins. Drugs 2000; 59(Suppl 3):29–35; discussion 47–9.
16. Nolet  BR. Update and overview of outpatient parenteral antimicrobial 
therapy regulations and reimbursement. Clin Infect Dis 2010; 51(Suppl 
2):S216–9.
17. Jena AB, Olenski AR, Blumenthal DM. Sex differences in physician salary in US 
public medical schools. JAMA Intern Med 2016; 176:1294–304.
18. Berrevoets  MA, Ten  Oever  J, Oerlemans  AJ, Kullberg  BJ, Hulscher  ME, 
Schouten JA. Quality indicators for appropriate outpatient parenteral antimicro-
bial therapy (OPAT) in adults: a systematic review and RAND-modified Delphi 
procedure. Clin Infect Dis. in press.
19. Shrestha NK, Bhaskaran A, Scalera NM, et al. Contribution of infectious disease 
consultation toward the care of inpatients being considered for community-based 
parenteral anti-infective therapy. J Hosp Med 2012; 7:365–9.
20. Shah A, Petrak R, Fliegelman R, et al. Infectious diseases specialty interven-
tion is associated with better outcomes among privately insured individuals 
receiving outpatient parenteral antimicrobial therapy. Clin Infect Dis 2019; 
68:1160–5.
21. Bhavan  KP, Brown  LS, Haley  RW. Self-administered outpatient antimicro-
bial infusion by uninsured patients discharged from a safety-net hospital: a 
propensity-score-balanced retrospective cohort study. PLoS Med 2015; 12 
(12):e1001922.
22. Schmidt  M, Hearn  B, Gabriel  M, et  al. Predictors of unplanned hospital-
ization in patients receiving outpatient parenteral antimicrobial therapy 
across a large integrated healthcare network. Open Forum Infect Dis 2017; 
4:XXX–XX.
23. Townsend J, Keller S, Tibuakuu M, et al. Outpatient parenteral therapy for com-
plicated Staphylococcus aureus infections: a snapshot of processes and outcomes 
in the real world. Open Forum Infect Dis 2018; 5:XXX–XX.
Appendix Table 1. Differences Between Respondents and Nonrespondents
Characteristics Respondents (n = 672), No. (%) Nonrespondents (n = 681), No. (%) P Value
Region of practice .76
 South 199 (29.6) 199 (29.2)
 West 157 (23.4) 159 (23.3)
 Midwest 167 (24.9) 159 (23.3)
 Northeast 145 (21.6) 156 (22.9)
 Puerto Rico or Canada 4 (0.6) 8 (1.2)
Years of experience .008
 <5 115 (17.1) 120 (17.6)
 5–14 238 (35.4) 278 (40.8)
 15–24 116 (17.3) 132 (19.4)
 >25 203 (30.2) 151 (22.2)
Primary respondent employment .03
 Hospital/clinic 235 (35.0) 234 (34.4)
 Private/group practice 177 (26.3) 178 (26.1)
 University/medical school 219 (32.6) 239 (35.1)
 VA and military 41 (6.1) 30 (4.4)
Primary respondent hospital .21
 Community hospital 178 (26.5) 207 (30.4)
 Nonuniversity teaching hospital 175 (26) 154 (22.6)
 University hospital 238 (35.4) 245 (36)
 VA or military hospital 46 (6.8) 34 (5)
 City/country hospital 35 (5.2) 41 (6)
Hospital bed size .34
 <200 beds 75 (11.2) 65 (9.5)
 200–350 beds 157 (23.4) 153 (22.5)
 351–450 beds 101 (15.0) 129 (18.9)
 451–600 beds 1365 (20.2) 127 (18.6)
 >600 beds 203 (30.2) 207 (30.4)
Current fellow-in-training 40 (5.9) 26 (3.8) .068
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